Laboratory of Tumor Immunology and Biology and Medical Oncology Branch, National Cancer Institute, Bethesda, Maryland.
Division of Genitourinary Malignancies, Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Los Angeles, California; Departments of Urology and Medicine, Tulane University School of Medicine, New Orleans, Louisiana.
Although treatment for prostate cancer has improved over the past several years, taxanes remain the only form of chemotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). In addition to the promising therapeutic cancer vaccines and newly developed agents targeting androgen receptor signaling, chemotherapy-based treatments will likely continue to play a significant role in patients with mCRPC. Recently published data that showed that a second taxane (cabazitaxel) extends survival after progression on docetaxel was a significant step forward, but also highlighted the need to overcome taxane resistance in prostate cancer. Preliminary evidence suggests that several treatment strategies may improve the activity of taxanes in prostate cancer and perhaps enhance clinical outcomes.
Written by:
Madan RA, Pal SK, Sartor O, Dahut WL. Are you the author?
Reference: Clin Cancer Res. 2011 Jun 15;17(12):3892-902.
doi: 10.1158/1078-0432.CCR-10-2654
PubMed Abstract
PMID: 21680545
UroToday.com Prostate Cancer Section
